论文部分内容阅读
目的检测早期直肠癌患者血清肿瘤型M2丙酮酸激酶(Tu M2-PK)含量并分析其与临床病理参数的相关性,探讨其在早期诊断中的价值。方法酶联免疫吸附法(ELISA)定量检测84例早期直肠癌、50例直肠良性病变及32名健康对照者血清Tu M2-PK水平,比较3组间Tu M2-PK的差异;分析直肠癌患者临床病理参数处于不同程度时Tu M2-PK阳性率的差异;Spearman法分析Tu M2-PK与不同临床病理参数的相关性。ROC曲线法分析Tu M2-PK诊断直肠癌TNM分期Ⅰ期、Ⅱ期的性能。结果直肠癌患者血清Tu M2-PK显著高于直肠良性病变患者与健康对照者,差异有统计学意义(P<0.05)。不同分化程度与不同TNM分期,Tu M2-PK阳性率差异有统计学意义(P<0.05);Tu M2-PK对直肠癌TNM分期Ⅰ期、Ⅱ期时曲线下面积分别为0.64、0.67;血清Tu M2-PK浓度与分化程度及TNM分期间存在正相关(r值分别为0.312、0.337,P<0.05)。结论早期直肠癌患者血清Tu M2-PK水平变化可辅助病情的判断,用于早期诊断。
Objective To detect the serum level of M2-PK in serum of patients with early rectal cancer and analyze its correlation with clinicopathological parameters and explore its value in early diagnosis. Methods The serum levels of Tu M2-PK in 84 patients with early rectal cancer, 50 patients with benign rectum and 32 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA), and the difference of Tu M2-PK between the 3 groups was analyzed. The difference of Tu M2-PK positive rate in different degree of clinicopathological parameters was analyzed by Spearman method. The correlation between Tu M2-PK and different clinicopathological parameters was analyzed by Spearman method. ROC curve analysis of Tu M2-PK TNM staging of rectal cancer stage Ⅰ, Ⅱ performance. Results The serum Tu M2-PK in patients with rectal cancer was significantly higher than that in patients with benign rectal lesions and healthy controls (P <0.05). The difference of Tu M2-PK positive rate was statistically significant (P 0. 05) between different differentiation degree and different TNM staging. The area under the curve of Tu M2-PK for stage I and II TNM staging of rectal cancer were 0.64 and 0.67 respectively. Serum There was a positive correlation between Tu M2-PK concentration and TNM stage (r = 0.312,0.337, P <0.05). Conclusion The changes of serum Tu M2-PK levels in early rectal cancer patients may help to determine the condition and be used for early diagnosis.